Less than a tenth of people eligible to benefit from obesity jabs including Wegovy are able to get them, states the World Health Organization as it publishes its first advice on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is urging more widespread and fairer availability to these injectable treatments.
According to projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"The new guidance affirms that obesity is a long-term condition that can be managed with holistic and lifelong care," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are significant obstacles to widespread access to the jabs that can assist patients in reducing significant body mass, explains the body.
Skinny Jab Shortage
Despite the current best projected outlook, the production of GLP-1 therapies would only suffice for around 100 million people – less than 10% of those who need them, as stated by the WHO.
The recommendation calls on nations and manufacturers to widen availability, by strategies such as voluntary licensing.
The intellectual property rights on the active ingredient – the primary component of the drug Wegovy – is due to expire in several nations in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs replicate a biological compound to reduce digestion speed, suppress the appetite and boost feelings of fullness so individuals consume fewer calories.
Individuals commonly begin shedding pounds after several weeks of starting on the regular doses.
Research indicates patients may put most of the weight back on within a year of stopping the medication, because their typical appetite resume.
Being carrying excess weight elevates your risk for developing medical conditions, such as diabetes, heart disease, stroke, and some malignancies.
Excess weight concerns people in all nations and was linked to 3.7 million deaths worldwide in 2024, according to the health agency.
